{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:34:30Z","timestamp":1707525270714},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,11]]},"DOI":"10.7759\/cureus.45062","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:11:12Z","timestamp":1694477472000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Significant Improvement of Heart Failure With Reduced Ejection Fraction With a Small Dose of Candesartan in a Hemodialysis Patient With Hypertensive Heart Disease and Nephrosclerosis"],"prefix":"10.7759","author":[{"given":"Haruhito","family":"Harada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiteru","family":"Higa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Wakasugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.131","article-title":"Arterial stiffness and pulse pressure in CKD and ESRD","volume":"82","author":"Briet M","year":"2012","unstructured":"Briet M, Boutouyrie P, Laurent S, London GM. Arterial stiffness and pulse pressure in CKD and ESRD. Kidney Int. 2012, 82:388-400. 10.1038\/ki.2012.131","journal-title":"Kidney Int"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328356c257","article-title":"Hypertension and vascular calcification: a vicious cycle?","volume":"30","author":"Rattazzi M","year":"2012","unstructured":"Rattazzi M, Bertacco E, Puato M, Faggin E, Pauletto P. Hypertension and vascular calcification: a vicious cycle?. J Hypertens. 2012, 30:1885-93. 10.1097\/HJH.0b013e328356c257","journal-title":"J Hypertens"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2022.04.006","article-title":"Microvascular dysfunction as a systemic disease: a review of the evidence","volume":"135","author":"Feuer DS","year":"2022","unstructured":"Feuer DS, Handberg EM, Mehrad B, Wei J, Bairey Merz CN, Pepine CJ, Keeley EC. Microvascular dysfunction as a systemic disease: a review of the evidence. Am J Med. 2022, 135:1059-68. 10.1016\/j.amjmed.2022.04.006","journal-title":"Am J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.hfc.2019.06.007","article-title":"Hypertension and heart failure","volume":"15","author":"Slivnick J","year":"2019","unstructured":"Slivnick J, Lampert BC. Hypertension and heart failure. Heart Fail Clin. 2019, 15:531-41. 10.1016\/j.hfc.2019.06.007","journal-title":"Heart Fail Clin"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.hfc.2019.06.005","article-title":"The evolution from hypertension to heart failure","volume":"15","author":"Sorrentino MJ","year":"2019","unstructured":"Sorrentino MJ. The evolution from hypertension to heart failure. Heart Fail Clin. 2019, 15:447-53. 10.1016\/j.hfc.2019.06.005","journal-title":"Heart Fail Clin"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.08314","article-title":"Hypertensive kidney injury and the progression of chronic kidney disease","volume":"70","author":"Griffin KA","year":"2017","unstructured":"Griffin KA. Hypertensive kidney injury and the progression of chronic kidney disease. Hypertension. 2017, 70:687-94. 10.1161\/HYPERTENSIONAHA.117.08314","journal-title":"Hypertension"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.949260","article-title":"Hypertension in chronic kidney disease: what lies behind the scene","volume":"13","author":"Ameer OZ","year":"2022","unstructured":"Ameer OZ. Hypertension in chronic kidney disease: what lies behind the scene. Front Pharmacol. 2022, 13:949260. 10.3389\/fphar.2022.949260","journal-title":"Front Pharmacol"},{"key":"ref8","unstructured":"Committee on Statistics and Surveys, Japanese Society for Dialysis Therapy. current status of chronic dialysis care in Japan. https:\/\/www.jsdt.or.jp\/overview\/index.html."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960240303","article-title":"Angiotensin receptor blockers: evidence for preserving target organs","volume":"24","author":"Carson P","year":"2001","unstructured":"Carson P, Giles T, Higginbotham M, Hollenberg N, Kannel W, Siragy HM. Angiotensin receptor blockers: evidence for preserving target organs. Clin Cardiol. 2001, 24:183-90. 10.1002\/clc.4960240303","journal-title":"Clin Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200323080-00007","article-title":"Candesartan cilexetil in haemodialysis patients","volume":"23","author":"Ottosson P","year":"2003","unstructured":"Ottosson P, Attman PO, Agren AC, Samuelsson O. Candesartan cilexetil in haemodialysis patients. Clin Drug Investig. 2003, 23:545-50. 10.2165\/00044011-200323080-00007","journal-title":"Clin Drug Investig"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl293","article-title":"Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study","volume":"21","author":"Takahashi A","year":"2006","unstructured":"Takahashi A, Takase H, Toriyama T, Sugiura T, Kurita Y, Ueda R, Dohi Y. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study. Nephrol Dial Transplant. 2006, 21:2507-12. 10.1093\/ndt\/gfl293","journal-title":"Nephrol Dial Transplant"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.20-671","article-title":"The use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers is associated with the recovered ejection fraction in patients with dilated cardiomyopathy","volume":"62","author":"Enzan N","year":"2021","unstructured":"Enzan N, Matsushima S, Ide T, et al.. The use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers is associated with the recovered ejection fraction in patients with dilated cardiomyopathy. Int Heart J. 2021, 62:801-10. 10.1536\/ihj.20-671","journal-title":"Int Heart J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.28.593","article-title":"Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling","volume":"28","author":"Takai S","year":"2005","unstructured":"Takai S, Kirimura K, Jin D, Muramatsu M, Yoshikawa K, Mino Y, Miyazaki M. Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res. 2005, 28:593-600. 10.1291\/hypres.28.593","journal-title":"Hypertens Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk W","year":"2017","unstructured":"Ouwerkerk W, Voors AA, Anker SD, et al.. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017, 38:1883-90. 10.1093\/eurheartj\/ehx026","journal-title":"Eur Heart J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2015.07.021","article-title":"Early vs. late reverse ventricular remodeling in patients with cardiomyopathy","volume":"68","author":"Banno A","year":"2016","unstructured":"Banno A, Kohsaka S, Inohara T, et al.. Early vs. late reverse ventricular remodeling in patients with cardiomyopathy. J Cardiol. 2016, 68:57-63. 10.1016\/j.jjcc.2015.07.021","journal-title":"J Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10080522","article-title":"Long-term effects of angiotensin receptor-neprilysin inhibitors on myocardial function in chronic heart failure patients with reduced ejection fraction","volume":"10","author":"Poglajen G","year":"2020","unstructured":"Poglajen G, An\u017ei\u010d-Drofenik A, Zemlji\u010d G, et al.. Long-term effects of angiotensin receptor-neprilysin inhibitors on myocardial function in chronic heart failure patients with reduced ejection fraction. Diagnostics (Basel). 2020, 10:522. 10.3390\/diagnostics10080522","journal-title":"Diagnostics (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.004876","article-title":"Ambulatory hypertension subtypes and 24-hour systolic and diastolic blood pressure as distinct outcome predictors in 8341 untreated people recruited from 12 populations","volume":"130","author":"Li Y","year":"2014","unstructured":"Li Y, Wei FF, Thijs L, et al.. Ambulatory hypertension subtypes and 24-hour systolic and diastolic blood pressure as distinct outcome predictors in 8341 untreated people recruited from 12 populations. Circulation. 2014, 130:466-74. 10.1161\/CIRCULATIONAHA.113.004876","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3109\/10641963.2015.1060981","article-title":"Hypertension subtypes and risk of cardiovascular diseases in a Mongolian population, inner Mongolia, China","volume":"38","author":"Li H","year":"2016","unstructured":"Li H, Kong F, Xu J, Zhang M, Wang A, Zhang Y. Hypertension subtypes and risk of cardiovascular diseases in a Mongolian population, inner Mongolia, China. Clin Exp Hypertens. 2016, 38:39-44. 10.3109\/10641963.2015.1060981","journal-title":"Clin Exp Hypertens"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200203000-00014","article-title":"Isolated diastolic hypertension, pulse pressure, and mean arterial pressure as predictors of mortality during a follow-up of up to 32 years","volume":"20","author":"Strandberg TE","year":"2002","unstructured":"Strandberg TE, Salomaa VV, Vanhanen HT, Pitk\u00e4l\u00e4 K, Miettinen TA. Isolated diastolic hypertension, pulse pressure, and mean arterial pressure as predictors of mortality during a follow-up of up to 32 years. J Hypertens. 2002, 20:399-404. 10.1097\/00004872-200203000-00014","journal-title":"J Hypertens"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.21.3301","article-title":"Prognosis of isolated systolic and isolated diastolic hypertension as assessed by self-measurement of blood pressure at home: the Ohasama study","volume":"160","author":"Hozawa A","year":"2000","unstructured":"Hozawa A, Ohkubo T, Nagai K, et al.. Prognosis of isolated systolic and isolated diastolic hypertension as assessed by self-measurement of blood pressure at home: the Ohasama study. Arch Intern Med. 2000, 160:3301-6. 10.1001\/archinte.160.21.3301","journal-title":"Arch Intern Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2016.05.012","article-title":"The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice","volume":"97","author":"Wang X","year":"2016","unstructured":"Wang X, Ye Y, Gong H, et al.. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice. J Mol Cell Cardiol. 2016, 97:180-90. 10.1016\/j.yjmcc.2016.05.012","journal-title":"J Mol Cell Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.058420","article-title":"Up-regulation of angiotensin II type 2 receptor in rat thoracic aorta by pressure-overload","volume":"308","author":"Yayama K","year":"2004","unstructured":"Yayama K, Horii M, Hiyoshi H, Takano M, Okamoto H, Kagota S, Kunitomo M. Up-regulation of angiotensin II type 2 receptor in rat thoracic aorta by pressure-overload. J Pharmacol Exp Ther. 2004, 308:736-43. 10.1124\/jpet.103.058420","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/169240-a-case-of-significant-improvement-of-heart-failure-with-reduced-ejection-fraction-with-a-small-dose-of-candesartan-in-a-hemodialysis-patient-with-hypertensive-heart-disease-and-nephrosclerosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:04:53Z","timestamp":1707509093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/169240-a-case-of-significant-improvement-of-heart-failure-with-reduced-ejection-fraction-with-a-small-dose-of-candesartan-in-a-hemodialysis-patient-with-hypertensive-heart-disease-and-nephrosclerosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.45062","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,11]]}}}